|
gptkbp:instanceOf
|
immune response
|
|
gptkbp:advantage
|
MHC-unrestricted cytotoxicity
easy expansion in vitro
low risk of graft-versus-host disease
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Phase_I
Phase II
Phase III
|
|
gptkbp:cytotoxicityMechanism
|
Fas/FasL pathway
perforin/granzyme pathway
|
|
gptkbp:discoveredBy
|
gptkb:Zhinan_Yin
|
|
gptkbp:discoveredIn
|
1991
|
|
gptkbp:expansion
|
gptkb:anti-CD3_antibody
gptkb:interferon-gamma
gptkb:interleukin-2
gptkb:interleukin-1
|
|
gptkbp:fullName
|
gptkb:Cytokine-Induced_Killer_cell
|
|
gptkbp:function
|
immunotherapy
tumor cell killing
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CIK cell
|
|
gptkbp:limitation
|
short in vivo persistence
variable efficacy
|
|
gptkbp:marking
|
gptkb:CD56
gptkb:NKG2D
gptkb:CD3
gptkb:CD4
gptkb:CD8
CD16
|
|
gptkbp:medicalUse
|
adoptive cell therapy
|
|
gptkbp:origin
|
peripheral blood mononuclear cells
|
|
gptkbp:relatedTo
|
gptkb:CAR-T_cell
T lymphocyte
natural killer cell
|
|
gptkbp:target
|
solid tumors
hematological malignancies
|
|
gptkbp:usedIn
|
clinical trials
cell-based immunotherapy
experimental cancer treatment
|
|
gptkbp:bfsParent
|
gptkb:Cytokine-induced_killer_cell
|
|
gptkbp:bfsLayer
|
6
|